Motley Fool Money cover image

Disney Has Its CEO

Motley Fool Money

00:00

Novo Nordisk's Outlook vs. Eli Lilly

Rachel explains Novo's expected declines, pricing deals, patent expiries, and contrasts Eli Lilly's accelerating GLP-1 growth.

Play episode from 13:34
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app